DMW - Deutsche Medizinische Wochenschrift, Table of Contents Dtsch Med Wochenschr 2006; 131(16): 909-919DOI: 10.1055/s-2006-939868 CME-Beitrag | Review articleGastroenterologie© Georg Thieme Verlag KG Stuttgart · New YorkGastroösophageale RefluxkrankheitGastroesophageal reflux diseaseJ. Labenz1 , D.-P Borkenstein1 , A. Leodolter1 , J. F. Riemann2 1Medizinische Klinik, Ev. Jung-Stilling-Krankenhaus Siegen 2Medizinische Klinik C, Klinikum Ludwigshafen Recommend Article Abstract Buy Article Schlüsselwörter Gastroösophageale Refluxkrankheit - nicht-erosive Refluxkrankheit - erosive Refluxkrankheit - Barrett-Ösophagus Key words gastro-oesophageal reflux disease - non-erosive reflux disease - erosive reflux disease - Barrett's oesophagus Full Text References Literatur 1 Adamek R, Wienbeck M. Ösophageale Motilitätsprofile bei gastroösophagealem Reflux - Konsequenzen für die Therapie. Leber Magen Darm. 1998; 28 245-248 2 Arguedas M R, Heudebert G R, Klapow J C. et al . Re-examination of the cost-effectiveness of surgical versus medical therapy in patients with gastroesophageal reflux disease: the value of long-term data collection. Am J Gastroenterol. 2004; 99 1023-1028 3 Armstrong D. Review article: towards consistency in the endoscopic diagnosis of BarrettŽs oesophagus and columnar metaplasia. Aliment Pharmacol Ther. 2004; 20 (Suppl 5) 40-47 4 Bell N J, Burget D, Howden C W, Wilkinson J, Hunt R H. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion. 1992; 51 (Suppl 1) 59-67 5 Borjesson M, Rolny P, Mannheimer C. et al . Nutcracker esophagus: a double-blind, placebo-controlled, cross-over study of the effects of lansoprazole. Aliment Pharmacol Ther. 2003; 18 1129-1135 6 Chiba N, De Gara C J, Wilkinson J M, Hunt R H. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology. 1997; 112 1798-1810 7 Chrysos E, Athanasakis E, Zoras O J. et al . Twenty-four-hour ambulatory versus stationary esophageal manometry in the evaluation of esophageal motility in patients with gastroesophageal reflux disease. Digestion. 2002; 66 1-8 8 Corley D A, Katz P, Wo J M. et al . Improvement of gastroesophageal reflux symptoms after radiofrequency energy: a randomized, sham-controlled trial. Gastroenterology. 2003; 125 668-676 9 Cremonini F, Wise J, Moayyedi P, Talley N J. Diagnostic and therapeutic use of proton pump inhibitors in non-cardiac chest pain: metaanalysis. Am J Gastroenterol. 2005; 100 1226-1232 10 Dean B B, Gano A D, Knight K. et al . Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol. 2004; 2 656-664 11 DeVault K R, Castell D O. American College of Gastroenterology. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol. 2005; 100 190-200 12 Devière J, Costamagna G, Neuhaus H. et al . Nonresorbable copolymer implantation for gastroesophageal reflux disease: a randomized sham-controlled multicenter trial. Gastroenterology. 2005; 128 532-540 13 Fackler W K, Ours T M, Vaezi M F, Richter J E. Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology. 2002; 122 625-632 14 Fang J. Nutcracker esophagus: GERD or an esophageal motility disorder. Am J Gastroenterol. 2002; 97 1556-1557 15 Fass R, Ofman J J. Gastroesophageal reflux disease - should we adopt a new conceptual framework?. Am J Gastroenterol. 2002; 97 1901-1907 16 Guda N, Partington S, Vakil N. Symptomatic gastro-oesophageal reflux, arousals and sleep quality in patients undergoing polysomnography for possible obstructive sleep apnoea. Aliment Pharmacol Ther. 2004; 20 1153-1159 17 Hansen A N, Bergheim R, Fagertun H, Lund H, Moum B. A randomised prospective study comparing the effectiveness of esomeprazole treatment strategies in clinical practice for 6 months in the management of patients with symptoms of gastroesophageal reflux disease. Int J Clin Pract. 2005; 59 665-671 18 Hansen A N, Wahlqvist P, Jorgensen E. et al . Six-month management of patients following treatment for gastroesophageal reflux disease symptoms - a Norwegian randomized, prospective study comparing the costs and effectiveness of esomeprazole and ranitidine treatment strategies in a general medical practitioners setting. Int J Clin Pract. 2005; 59 655-664 19 Howden C W, Henning J M, Huang B, Lukasik N, Freston J W. Management of heartburn in a large, randomized, community-based study: comparison of four therapeutic strategies. Am J Gastroenterol. 2001; 96 1704-1710 20 Johnson D A, Orr W C, Crawley J A. et al . Effect of esomeprazole on nighttime heartburn and sleep quality in patients with GERD: a randomized, placebo-controlled trial. Am J Gastroenterol. 2005; 100 1914-1922 21 Koop H, Schepp W, Muller-Lissner S. et al . Gastroösophageale Refluxkrankheit - Ergebnisse einer evidenzbasierten Konsensuskonferenz der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten. Z Gastroenterol. 2005; 43 163-194 22 Kulig M, Nocon M, Vieth M. et al . Risk factors of gastroesophageal reflux disease: methodology and first epidemiological results of the ProGERD study. J Clin Epidemiol. 2004; 57 580-589 23 Labenz J, Borkenstein D P. Pathophysiologie und Diagnostik der Refluxkrankheit. Internist. 2003; 44 11-20 24 Labenz J, Malfertheiner P. Treatment of uncomplicated reflux disease. World J Gastroenterol. 2005; 11 4291-4299 25 Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999; 340 825-831 26 Martinez S D, Malagon I B, Garewal H S, Cui H, Fass R. Non-erosive reflux disease (NERD) - acid reflux and symptom patterns. Aliment Pharmacol Ther. 2003; 17 537-545 27 Meining A, Classen M. The role of diet and lifestyle measures in the pathogenesis and treatment of gastroesophageal reflux disease. Am J Gastroenterol. 2000; 95 2692-2697 28 Morse C A, Quan S F, Mays M Z. et al . Is there a relationship between obstructive sleep apnea and gastroesophageal reflux disease?. Clin Gastroenterol Hepatol. 2004; 2 761-768 29 Numans M E, Lau J, de Wit N J, Bonis P A. Short-term treatment with proton pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics. Ann Intern Med. 2004; 140 518-527 30 Richter J E. Review article: extraoesophageal manifestations of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2005; 22 (Suppl 1) 70-80 31 Shaheen N J. Advances in BarrettŽs esophagus and esophageal adenocarcinoma. Gastroenterology. 2005; 128 1544-1566 32 Shaw M. Diagnostic utility of reflux disease symptoms. Gut. 2004; 53 (Suppl IV) 28-34 33 Sjöstedt S, Befrits R, Sylvan A. et al . Daily treatment with esomeprazole is superior to that taken on-demand for maintenance of healed erosive oesophagitis. Aliment Pharmacol Ther. 2005; 22 183-191 34 Tsai H H, Chapman R, Shepherd A. et al . Esomeprazole 20 mg on-demand is more acceptable to patients than continous lansoprazole 15 mg in the long-term maintenance of endoscopy-negative gastro-oesophageal reflux patients: the COMMAND study. Aliment Pharmacol Ther. 2004; 20 657-665 35 Watson R G, Tham T C, Johnston B T, McDougall N I. Double blind cross-over study of omeprazole in the treatment of patients with symptoms and physiological levels of acid reflux - the „sensitive oesophagus”. Gut. 1997; 40 587-590 Prof. Dr. med. J. Labenz Medizinische Fakultät der Universität Duisburg-Essen, Medizinische Klinik, Ev. Jung-Stilling-Krankenhaus Wichernstraße 40 57074 Siegen Phone: 0271/3334569 Fax: 0271/3334242 Email: J.Labenz@t-online.de
